Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market. These market leaders, however, face patent expirations and consequent biosimilar launches.
Author: Astrid Kurniawan
Publisher: Datamonitor Healthcare
Published: 6 March 2016
Number of pages:24
Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market. These market leaders, however, face patent expirations and consequent biosimilar launches. Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. The rate of this erosion is likely to be gradual initially, as both physicians and payers are not likely to advocate patient switching.
4 EXECUTIVE SUMMARY
5 Inflectra carries biosimilar labeling designation, but is not interchangeable
5 Physicians hesitant to use biosimilars, but understand that payers may hold sway
9 FIVE MAJOR EU MARKETS
9 Insights and strategic recommendations
9 Uptake of biosimilar TNF-alpha inhibitors varies across EU markets as the EMA does not determine interchangeability
9 Most physicians and payers consider biosimilars to be interchangeable, and an opportunity to reduce costs, but worries around indication extrapolation remain
11 Payers use biosimilars to pressure originators on pricing
12 Hospitals continue to procure both biosimilars and originators; dynamic pricing environment observed
15 Biosimilars will be used as price benchmarks for pipeline agents
16 Payers are unlikely to implement strong incentives to drive uptake of biosimilar infliximab due to limited use of the drug
23 Primary research
LIST OF TABLES
20 Table 1: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
Table 1: Market access tools used to promote biosimilar uptake in the five major EU markets, by country
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.